A deal in the next month and a half would be good. Otherwise I might start getting worried.
I'll be happy with any deal that provides enough up front for them to avoid any more capital raisings and keep the rest of the product pipeline moving, but I think there's a chance it could be a quite significant sum. KV (over)paid Vivus US$150 million for Evamist, but that kind of sum actually seems reasonable for Axiron.
- Forums
- ASX - By Stock
- acrux update /bioshares
ACR
acrux limited
Add to My Watchlist
0.00%
!
1.6¢

A deal in the next month and a half would be good. Otherwise I...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.524M |
Open | High | Low | Value | Volume |
1.5¢ | 1.6¢ | 1.5¢ | $9.887K | 624.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6355 | 1.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.7¢ | 20000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6355 | 0.016 |
4 | 559314 | 0.015 |
3 | 420000 | 0.014 |
2 | 397000 | 0.013 |
1 | 80000 | 0.012 |
Price($) | Vol. | No. |
---|---|---|
0.017 | 20000 | 1 |
0.018 | 252359 | 2 |
0.019 | 677115 | 3 |
0.020 | 50000 | 1 |
0.021 | 203466 | 1 |
Last trade - 15.00pm 26/06/2025 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online